Anti-Human PD-L1 (CD274) (Clone 29E.2A3) – Dylight® 488

Full length Human PD-L1

This DyLight® 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.

Liquid

Functional grade preclinical antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

This DyLight® 488 conjugate is stable when stored at 2-8°C. Do not freeze.

Research Use Only

2-8°C Wet Ice

Blue Laser (493 nm)

Human PD-L1 (CD274)

PD-L1 is commonly expressed on the surface of antigen presenting cells (macrophages, activated B cells, dendritic cells), some epithelial cells under inflammatory conditions, some activated T cells, and several types of tumors as well as tumor infiltrating immune cells. PD-L1 can also exist in a soluble form (sPD-L1) in myeloid-derived cells (monocytes, macrophages, and dendritic cells) and several human cancer lines.

Programmed cell death 1 ligand 1 (PD-L1; CD274; B7-H1) is a type I transmembrane glycoprotein widely expressed in many types of tissues that acts as a ligand for the immune inhibitory receptor programmed cell death 1 (PD-1; CD279)^{1, 2, 3}. The PD-1 pathway is responsible for T cell activation, proliferation, and cytotoxic secretion, with PD-1/PD-L1 interaction triggering inhibitory signals that dampen T cell function. PD-L1 also plays a critical role in the differentiation of inducible regulatory T cells⁴.

In normal tissues, PD-L1/PD-1 ligation is crucial to maintaining homeostasis of the immune system and preventing autoimmunity during infection and inflammation⁴. In the tumor microenvironment, their interaction provides an immune escape mechanism for tumor cells by turning off cytotoxic T cells. As such, blocking the PD-L1/PD-1 interaction is a target of many anti-cancer immunotherapies.

29E.2A3 was generated by immunizing female BALB/c mice with purified hPD-L1 cDNA⁵. Spleen cells were fused with SP2/0 myeloma cells, and the resulting hybridomas were screened by ELISA for reactivity against hPD-L1–Ig fusion protein followed by cell-surface staining of hPD-L1–transfected Chinese hamster ovary cells and 300.19 cells.

PD-1 (CD279)

1. Freeman GJ, Long AJ, Iwai Y, et al. J Exp Med. 2000192(7):1027-1034. 2000.
2. Tsai KK, Zarzoso I, Daud AI. Hum Vaccin Immunother. 10(11):3111-3116. 2014.
3. Han Y, Liu D, Li L. Am J Cancer Res. 10(3):727-742. 2020.
4. Dermani FK, Samadi P, Rahmani G, et al. J Cell Physiol. 234(2):1313-1325. 2019.
5. Latchman Y, Wood CR, Chernova T, et al. Nat Immunol. 2(3):261-268. 2001.
6. Brown JA, Dorfman DM, Ma FR, et al. J Immunol. 170(3):1257-1266. 2003.
7. Cai G, Karni A, Oliveira EM, et al. Cell Immunol. 230(2):89-98. 2004.
8. Porichis F, Hart MG, Zupkosky J, et al. J Virol. 88(5):2508-2518. 2014.
9. Hughes MJ, McGettrick HM, Sapey E. J Immunol Methods. 483:112795. 2020.
10. Boyerinas B, Jochems C, Fantini M, et al. Cancer Immunol Res. 3(10):1148-1157. 2015.
11. Nakamoto N, Cho H, Shaked A, et al. PLoS Pathog. 5(2):e1000313. 2009.
12. Hegde S, Lockridge JL, Becker YA, et al. J Autoimmun. 37(1):28-38. 2011.
13. Broos K, Lecocq Q, Keersmaecker B, et al. Vaccines (Basel). 7(3):85. 2019.
14. Darga EP, Dolce EM, Fang F, et al. PLoS One. 16(11):e0260124. 2021.